Table 2.
Descriptive statistics for glycaemic regulation and AChE/Hb across project phases
| Phase I (Sept.–Oct. 2018) |
Phase II (Nov.–Dec. 2018) |
Phase III (Jan.–Feb. 2019) |
Δ/phase | |
| HbA1c (mmol/mol), <LOQ excluded |
34.11±8.86 | 33.57±7.99 | 35.19±8.80 | 0.56 (0.12 to 1.00) |
| n | 354 | 343 | 339 | |
| HbA1c (mmol/mol), <LOQ imputed |
33.64±9.19 | 33.10±8.36 | 34.41±9.37 | 0.41 (−0.03 to 0.85) |
| n | 364 | 353 | 354 | |
| HbA1c (% NGSP), <LOQ excluded |
5.27±0.81 | 5.22±0.73 | 5.37±0.80 | 0.05 (0.01 to 0.09) |
| n | 354 | 343 | 339 | |
| HbA1c (% NGSP), <LOQ imputed |
5.23±0.84 | 5.18±0.76 | 5.30±0.85 | 0.04 (−0.00 to 0.08) |
| n | 364 | 353 | 354 | |
| FPG (mmol/mol) | 5.08±0.85 | 5.25±0.74 | 5.09±1.12 | −0.03 (−0.11 to 0.04) |
| n | 128 | 210 | 253 | |
| AChE (U/mL) | 3.12±0.57 | 3.00±0.55 | 2.89±0.53 | −0.12 (−0.14 to −0.10) |
| n | 364 | 353 | 354 | |
| Hb (g/L) | 118.8±13.6 | 114.7±14.4 | 116.6±13.0 | −1.3 (−1.8 to −0.7) |
| n | 364 | 353 | 354 | |
| AChE/Hb (U/g) | 26.31±3.96 | 26.23±4.13 | 24.84±3.70 | −0.74 (−0.85 to −0.63) |
| n | 364 | 353 | 354 |
Data from each phase presented as mean±SD. Δ/phase denotes the mean change (95% CI) when project phase changes increases by one, based on a mixed effect model with fixed effect for phase, random effects for family and person.
AChE, erythrocyte acetylcholinesterase; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; LOQ, limit of quantitation; NGSP, National Glycohemoglobin Standardization Program.